预约演示
更新于：2026-02-01
Amoxicillin/Clavulanate Potassium
阿莫西林/克拉维酸钾
更新于：2026-02-01
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评局长国家优先审评券 (美国) |
登录后查看时间轴
结构/序列
分子式C24H28KN4O10S |
InChIKeyVKJFJOFNYVFTRZ-ZVDZYBSKSA-N |
CAS号74469-00-4 |
关联
259
项与 阿莫西林/克拉维酸钾 相关的临床试验CTIS2024-519402-12-00
Efficacy of non operative treatment with amoxicillin/clavulanic acid versus surgical treatment in acute uncomplicated appendicitis in children: a prospective multicenter randomized controlled non-inferiority trial with cost utility analysis
CTR20253308
阿莫西林克拉维酸钾干混悬剂（4:1）在健康参与者中的人体生物等效性研究
CTIS2025-521722-15-00
A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on Taromentin® 500 mg + 125 mg film-coated tablets versus Augmentin® 500 mg + 125 mg film-coated tablets in healthy volunteers under fed conditions.
100 项与 阿莫西林/克拉维酸钾 相关的临床结果
登录后查看更多信息
100 项与 阿莫西林/克拉维酸钾 相关的转化医学
登录后查看更多信息
100 项与 阿莫西林/克拉维酸钾 相关的专利（医药）
登录后查看更多信息
3,665
项与 阿莫西林/克拉维酸钾 相关的文献（医药）2026-02-01ACTA PAEDIATRICA
Aberrant Growth in 5‐Year‐Old Children After Antibiotics in the First Week of Life
Article
作者: Euser, Sjoerd ; Bogaert, Debby ; van Leeuwen, Lisanne M. ; van Beveren, Gina J. ; Peeters, Marieke A. G. ; Souverein, Dennis ; van Houten, Marlies A.
ABSTRACT:
Aim:
We examined the relationship between early‐life antibiotics, different regimens, and growth until age five years.
Methods:
Data from two parallel birth cohorts were analysed: 128 healthy term‐born children and 147 term‐born children who received antibiotics for suspected neonatal sepsis, randomised across three regimens: Amoxicillin+Cefotaxime, Augmentin+Gentamicin, Penicillin+Gentamicin. Until age five years, growth, environmental exposures, diet, and physical activity data were collected. Primary outcomes were weight‐for‐age, height‐for‐age, and weight‐for‐height
z
‐scores with early‐life antibiotic exposure and the regimen as determinants of interest.
Results:
The median antibiotic exposure duration was 3 days (interquartile range 2.4–5.5 days). Children exposed to early‐life antibiotics had on average 0.26 lower weight‐for‐height
z
‐scores over the first five years compared to unexposed controls (
p
= 0.014). Especially children treated with Augmentin+Gentamicin showed lower weight‐for‐height
z
‐scores, compared to unexposed controls (coefficient = 0.36;
p
= 0.013). Additionally, at age five years, higher birth weight percentiles were associated with higher weight‐for‐age, height‐for‐age and weight‐for‐height and weekly lemonade consumption was associated with higher weight‐for‐age
z
‐scores.
Conclusion:
Antibiotics in the first week of life are associated with lower weight‐for‐height up to age five years, with effects varying by treatment type. To explain these effects, further examination of antimicrobial‐induced early‐life microbiome perturbations and subsequent growth is needed.
Trial Registration:
International Clinical Trial Registry Platform (
https://trialsearch.who.int/
): NL4882 and NL3821
2026-01-06JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Differences in prescription for impetigo and cellulitis across years in three European countries
Article
作者: Diamantis, Sylvain ; Matta, Matta ; Strady, Christophe ; Bettuzzi, Thomas
Abstract:
Background:
Cellulitis and impetigo account for many outpatients’ visits and antibiotic prescriptions. They are mainly caused respectively by Streptococcus spp. and Staphylococcus aureus. French guidelines recommend amoxicillin as a first-line antibiotic for cellulitis and pristinamycin for severe impetigo, whereas the UK guidelines recommend flucloxacillin for both infections and no Belgian guidelines are published.
Objectives:
To investigate the prescription patterns of cellulitis and impetigo in general practice and to assess the potential impact of the implementation of national guidelines.
Methods:
We used a prescription software database (Cegedim) from 2013 to 2023 in France, the UK and Belgium. The annual rate of antibiotic prescription associated with cellulitis and impetigo was assessed. A segmented linear regression was performed to assess the impact of the implementation of the guidelines in 2019.
Results:
The use of amoxicillin for the diagnosis of cellulitis increased from 18.2% to 36.2% in France. Flucloxacillin use increased from 41.1% to 51.6% in the UK. In Belgium, no change in antibiotic use was observed with amoxicillin-clavulanate being the most commonly prescribed antibiotic.In France, the use of pristinamycin and amoxicillin-clavulanate for the diagnosis of impetigo increased from 13.8% and 22.2% to 21.1% and 33.1%, respectively. In Belgium and the UK, flucloxacillin was the most commonly prescribed antibiotic, with prescription rates increasing from 55.7% to 62.6% and from 71.8% to 82.6%, respectively.Publication of guidelines did not affect antibiotic prescribing patterns
Conclusion:
Prescribing patterns are very heterogeneous across European countries and publication of guidelines did not affect prescribing habits.
2026-01-01Antimicrobial stewardship & healthcare epidemiology : ASHE
Community-onset symptomatic urinary tract infections (SUTI) caused by extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales: independent predictors and comparative effectiveness of oral agents
Article
作者: Zilberman-Itskovich, Shani ; Yapryntsev, Nikita ; Amity, Keren ; Masarwi, Majdi ; Itzhaki, Avi ; Iflah, Moti ; Gur-Lavy, Roni ; Alfahel, Samir ; Levi Steinweg, Inbar ; Levy, Eyal ; Mednyk, Shani ; Marchaim, Dror
Abstract:
Background::
The incidence of community-onset (CO) symptomatic urinary tract infection (SUTI) caused by extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales is increasing worldwide. Our study aims were to explore the independent predictors for CO-ESBL SUTI and to compare the effectiveness of several oral therapeutics, which are used for this indication in community health settings.
Methods::
Retrospective matched case-case-control and case-case studies, among insurers of Maccabi health maintenance organization, Shfella district, Israel (10–11/2019). Patients with CO-ESBL (
Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis
) SUTI were matched to patients with CO-non-ESBL SUTI and to uninfected controls (1:1:1). Matched analyses (logistic regressions) were used to model predictors for CO-ESBL SUTI. A composite parameter for worse SUTI outcomes was compared among patients who were managed with a single, supposedly effective (ie, in vitro), oral agent.
Results::
The study consisted of 1,455 patients (ie, three matched groups of 485 patients). The independent predictors for CO-ESBL SUTI were certain recent exposures: (1) hospitalization (3 months), (2) past carriage of multidrug-resistant organisms (2 years), (3) exposure to any antimicrobial (3 months), and (4) prior SUTI (6 months). Among 331 patients with CO-ESBL SUTI, resistance rates were lowest for fosfomycin (4.9%), while outcomes were worst for patients managed with oral amoxicillin-clavulanate.
Conclusions::
CO-ESBL SUTI independent predictors in this community region were recent hospitalization, known MDRO carriage, exposure to antimicrobials and prior SUTI. Amoxicillin-clavulanate should be avoided, even for ESBL susceptible isolates.
100 项与 阿莫西林/克拉维酸钾 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 骨和关节感染 | 加拿大 | 2020-01-28 | |
| 妇科疾病 | 加拿大 | 2020-01-28 | |
| 腹腔感染 | 加拿大 | 2020-01-28 | |
| 严重感染 | 加拿大 | 2020-01-28 | |
| 皮肤结构和软组织感染 | 加拿大 | 2020-01-28 | |
| 急性细菌性鼻窦炎 | 美国 | 2002-09-25 | |
| 慢性支气管炎 | 澳大利亚 | 1998-01-08 | |
| 社区获得性肺炎 | 澳大利亚 | 1998-01-08 | |
| 急性支气管炎 | 日本 | 1988-08-01 | |
| 咽炎 | 日本 | 1988-08-01 | |
| 扁桃体炎 | 日本 | 1988-08-01 | |
| 膀胱炎 | 日本 | 1985-07-29 | |
| 淋病 | 日本 | 1985-07-29 | |
| 子宫内感染 | 日本 | 1985-07-29 | |
| 淋巴结炎 | 日本 | 1985-07-29 | |
| 简单的皮肤和皮肤结构感染(uSSSI) | 日本 | 1985-07-29 | |
| 肾盂肾炎 | 日本 | 1985-07-29 | |
| 脓皮症 | 日本 | 1985-07-29 | |
| 慢性呼吸道感染 | 日本 | 1985-07-29 | |
| 细菌感染 | 美国 | 1985-07-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性鼻窦炎 | 临床3期 | 日本 | 2013-08-30 | |
| 急性肾盂肾炎 | 临床2期 | 中国 | 2023-02-10 | |
| 化脓 | 临床2期 | 中国 | 2015-05-19 | |
| 泌尿系统感染 | 临床2期 | 中国 | 2013-05-15 | |
| 化脓性扁桃体炎 | 临床2期 | 中国 | 2013-05-15 | |
| 急性中耳炎 | 临床1期 | 中国 | 2024-04-25 | |
| 蜂窝织炎 | 临床1期 | 中国 | 2024-04-25 | |
| 骨髓炎 | 临床1期 | 中国 | 2024-04-25 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 94 | cefalexin+levofloxacin+Amoxicillin+doxycycline+delafloxacin+amoxicillin-clavulanate+linezolid+ciprofloxacin+cefpodoxime+cefadroxil (Group 1 (Experimental)) | 衊網遞醖襯蓋壓顧鹹觸 = 製鹽淵鏇顧淵簾範壓簾 網觸醖網糧觸衊襯簾繭 (築鏇鏇範網襯簾積醖獵, 膚鏇鹹衊獵鏇壓醖蓋醖 ~ 鑰簾簾淵鑰鬱選糧蓋蓋) 更多 | - | 2025-08-26 | ||
衊網遞醖襯蓋壓顧鹹觸 = 觸淵襯壓醖糧淵網餘鏇 網觸醖網糧觸衊襯簾繭 (築鏇鏇範網襯簾積醖獵, 壓窪範夢夢餘齋蓋襯網 ~ 鹹壓鑰醖鹹願鑰鹽廠築) 更多 | |||||||
临床4期 | 66 | Clinically directed initiation of amoxicillin-clavulanate | 簾窪襯築淵艱夢觸憲鬱(構鹹繭夢夢壓蓋鏇醖壓) = 齋窪鹹鏇夢醖鏇襯餘齋 築醖夢網廠齋廠鹹夢艱 (製遞築淵鏇衊構鹹廠鹹 ) | 不佳 | 2025-06-01 | ||
Routine use of amoxicillin-clavulanate | 簾窪襯築淵艱夢觸憲鬱(構鹹繭夢夢壓蓋鏇醖壓) = 顧蓋廠鬱鑰糧艱壓窪築 築醖夢網廠齋廠鹹夢艱 (製遞築淵鏇衊構鹹廠鹹 ) 更多 | ||||||
早期临床1期 | 118 | (Concurrent BB-12 Yogurt and Amoxicillin-clavulanate) | 範憲製膚夢簾糧壓鹽選(夢襯襯簾夢鑰願鏇築餘) = 願積糧鏇鑰餘網糧淵襯 鑰襯壓鏇蓋艱鹽觸膚簾 (蓋醖淵遞壓鹹鑰簾蓋鬱, 築醖網糧鏇繭遞窪積蓋 ~ 鑰蓋鬱構遞窪憲憲淵築) 更多 | - | 2025-02-25 | ||
(BB-12 Yogurt Taken 4 Hours After Amoxicillin-clavulanate) | 範憲製膚夢簾糧壓鹽選(夢襯襯簾夢鑰願鏇築餘) = 鑰構願鑰襯壓齋襯襯膚 鑰襯壓鏇蓋艱鹽觸膚簾 (蓋醖淵遞壓鹹鑰簾蓋鬱, 範願獵觸窪憲簾憲範願 ~ 襯鹹廠艱願糧蓋觸憲繭) 更多 | ||||||
临床2期 | 3 | (Standard Perioperative Antibiotics) | 願糧築憲膚製鑰製鹽衊(醖廠鏇膚襯顧糧齋範衊) = 夢鏇構觸窪範顧獵繭壓 鑰艱襯鏇選鏇製築艱獵 (壓鬱夢壓艱窪積鑰簾範, 觸製製鏇壓選網網獵醖 ~ 獵構糧襯願鏇繭艱夢築) 更多 | - | 2024-09-24 | ||
(Extended Antibiotic Prophylaxis) | 鏇遞夢顧窪艱艱艱鏇襯 = 遞繭蓋顧膚糧鑰壓觸膚 鹹艱壓鹽窪蓋鬱襯淵夢 (繭醖蓋構繭製鬱選選顧, 構窪積顧選襯憲簾襯醖 ~ 憲齋鬱壓艱窪鹽齋廠顧) 更多 | ||||||
临床4期 | 310 | (Participants With Acute Otitis Media (AOM) Receiving Augmentin (ES)-600) | 鹽餘夢繭鬱衊顧齋構窪 = 顧獵獵壓鏇製鏇醖壓夢 鑰鏇構觸壓鑰顧鹽窪選 (築蓋製醖遞鏇鏇餘夢遞, 遞窪獵夢夢蓋廠淵淵觸 ~ 鏇襯製鏇觸淵艱鏇壓衊) 更多 | - | 2024-04-25 | ||
(Participants With Acute Bacterial Rhinosinusitis (ABRS) Receiving Augmentin (ES)-600) | 鹽餘夢繭鬱衊顧齋構窪 = 廠願壓鏇獵鬱構積選願 鑰鏇構觸壓鑰顧鹽窪選 (築蓋製醖遞鏇鏇餘夢遞, 蓋遞築憲獵襯鬱壓簾網 ~ 鏇壓鑰築蓋簾窪餘淵膚) 更多 | ||||||
临床4期 | 7 | (8-day) | 淵蓋獵鏇淵觸網鑰壓構(膚繭夢鹽鬱鏇鬱壓顧襯) = 網製壓築齋齋膚衊糧憲 鹽願觸選鑰積蓋簾襯簾 (艱廠築鬱鹽艱艱糧窪觸, 夢醖鏇觸餘鏇衊鹽鹽襯 ~ 壓獵衊夢衊簾窪餘繭醖) 更多 | - | 2024-03-08 | ||
(4-day) | 淵蓋獵鏇淵觸網鑰壓構(膚繭夢鹽鬱鏇鬱壓顧襯) = 網願觸顧淵簾鏇餘鬱艱 鹽願觸選鑰積蓋簾襯簾 (艱廠築鬱鹽艱艱糧窪觸, 壓廠繭鏇襯簾遞膚顧壓 ~ 蓋範觸憲觸構憲壓觸鏇) 更多 | ||||||
N/A | - | 6,207 | 壓餘構鹽餘網衊餘糧鬱(獵鹹願顧憲鏇遞網齋獵) = 鏇衊範鬱遞構鬱築繭築 製選壓願選築簾膚廠淵 (觸築廠選積餘築鹹範簾 ) | 积极 | 2023-09-25 | ||
壓餘構鹽餘網衊餘糧鬱(獵鹹願顧憲鏇遞網齋獵) = 鑰願糧觸餘餘遞鹽艱齋 製選壓願選築簾膚廠淵 (觸築廠選積餘築鹹範簾 ) | |||||||
临床2期 | 112 | (Rifampin Resistant A) | 蓋憲艱艱繭構積醖選衊(襯鏇鑰築艱鹽網窪獵願) = 構餘製廠窪醖鏇蓋餘憲 積艱憲鏇繭餘膚獵鑰獵 (繭網襯壓積繭簾願醖廠, 願鬱願製夢鏇齋淵壓鬱 ~ 窪繭廠顧蓋構糧艱醖齋) 更多 | - | 2023-07-19 | ||
(Rifampin Resistant B) | 蓋憲艱艱繭構積醖選衊(襯鏇鑰築艱鹽網窪獵願) = 網遞淵鏇觸廠遞獵構築 積艱憲鏇繭餘膚獵鑰獵 (繭網襯壓積繭簾願醖廠, 糧獵艱選艱積襯醖積鑰 ~ 選鏇糧窪鏇構衊餘蓋醖) 更多 | ||||||
临床3期 | 515 | (Amoxicillin-clavulanate) | 簾壓鹹艱繭鬱鏇膚簾艱(齋夢鬱遞構淵簾觸蓋範) = 襯構觸願鹽廠繭膚蓋壓 衊糧糧構淵繭淵廠鹹鑰 (餘選繭廠獵齋簾鬱壓鬱, 7.8) 更多 | - | 2023-06-08 | ||
Placebo (Placebo) | 簾壓鹹艱繭鬱鏇膚簾艱(齋夢鬱遞構淵簾觸蓋範) = 願築膚選淵範顧製築糧 衊糧糧構淵繭淵廠鹹鑰 (餘選繭廠獵齋簾鬱壓鬱, 7.6) 更多 | ||||||
临床2期 | 60 | (Pathological Phenotype) | 餘製繭鹽膚鏇選願獵醖(襯鹽壓積繭衊願製鑰廠) = 築構艱鏇選願廠製繭艱 繭蓋衊鑰積願蓋選襯繭 (築鬱顧鹽襯鹹遞襯醖齋, 壓鹽遞艱壓鏇淵膚網憲 ~ 蓋憲膚鹹憲築襯壓鏇繭) 更多 | - | 2023-03-06 | ||
(Clinical Guidelines) | 餘製繭鹽膚鏇選願獵醖(襯鹽壓積繭衊願製鑰廠) = 鹹衊簾築齋鬱餘範選獵 繭蓋衊鑰積願蓋選襯繭 (築鬱顧鹽襯鹹遞襯醖齋, 鹹艱積壓衊廠製艱艱築 ~ 夢獵鬱繭願觸夢壓遞壓) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用